- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04864938
Recovery After Critical Covid-19 Infection (RECOVID)
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Eligible patients who have been treated in the intensive care units of Helsinki University Hospital are invited to participate. Controls are recruited from follow-up clinics, and with announcements in media and websites.
The participants receive an invitation to a follow-up clinic where their experiences from the ICU treatment and recovery will be discussed. The investigators will perform neuropsychologic testing (6 months post-discharge), a telephone interview (3 months) and send written questionnaires (3, 6 and 24 months) to the participants. The participants will undergo MRI imaging of the brain and laboratory tests will be taken. The olfactory function will be tested at a follow-up clinic. Data on the patients´ respiratory function from clinical spirometry and diffusion capacity testing 3 and 6 months after discharge are collected. The patients will perform a 6 min walk test.
Data on coagulation laboratory values will be registered from acute phase and 6 months after discharge. The investigators will also analyse ApoE alleles, neurofilament light and NAD-metabolites and study their correlation with neuropsychologic findings and long term symptoms (up to 5 years after hospital discharge).
Participants will also undergo magnetic resonance imaging of the heart at 6-12 months after the hospital discharge, and laboratory samples, a symptom questionnaire and electrocardiogram are collected. Inflammatory parameters and variables associated with regulating inflammation and coagulation will be analysed.
Clinical data from the acute and post-acute phase and demographic data are collected from the patient data management systems.
The target patient number is 75 intensive care treated patients and 50 control persons in each three control group.
Tipo de estudio
Inscripción (Anticipado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Capital Province Of Finland
-
Helsinki, Capital Province Of Finland, Finlandia, 00290
- Helsinki university hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Age 18-100
- Positive PCR for Sars-CoV-2 (except non-covid controls, who must be negative)
- Native language Finnish or Swedish
- Informed consent to study to study participation
Exclusion Criteria:
- Age under 18
- Pregnant or lactating
- Major neurologic diagnosis (TBI, dementia, stroke, Parkinson´s disease before covid-19)
- Substantially impaired hearing or vision
- Developmental disability.
- No consent to study participation
- Contraindication to MR imaging (such as cardiac pacemaker, allergy to contrast)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Patients: ICU treated covid-19 patients
Neuropsychologic testing Respiratory function testing, chest x-ray and 6 minute walk test MRI of the brain and heart Laboratory tests Olfactory function tests Neuropsychology questionnaires
|
|
Control group 1, covid-19 patients treated in the regular wards
As above, without 6 minute walk test or routine chest x-ray
|
|
Control group 2, persons with covid-19 without hospitalization
As above, but without respiratory testing
|
|
Control group 3, non-covid controls
As control group 2
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cognitive function 6 months after hospital discharge
Periodo de tiempo: 6 months after hospital discharge
|
Global score calculated from three domains: memory, executive functions and attention.Memory: WMS-III Word list delayed recall + WMS-III Logical memory delayed recall + Rey Complex Figure, delayed recall Executive: TMB (time, reversed) + Stroop interference (time, reversed) + FAB score Attention: WAIS-IV Coding + CPT (correct items) + Stroop naming (time, reversed) The global score will be compared with controls and age matched national references
|
6 months after hospital discharge
|
|
Diffusion capacity 6 months after hospital discharge
Periodo de tiempo: 6 months after hospital discharge
|
Diffusion capacity DLCO results (percentage of predicted) 6 months after ICU treatment for covid-19
|
6 months after hospital discharge
|
|
Incidence of post myocarditis findings in MRI of the heart
Periodo de tiempo: 6-12 months after hospital discharge
|
Incidence of findings in cardiac MRI indicating previous myocarditis in each group
|
6-12 months after hospital discharge
|
|
Six minute walk test distance
Periodo de tiempo: 6 months after hospital discharge
|
The distance in meters walked by ICU treated patients in 6 minutes in controlled test environment
|
6 months after hospital discharge
|
|
Restriction in lung function tests
Periodo de tiempo: 6 months after hospital discharge
|
Restriction in lung function parameters vital capacity and forced vital capacity (z-scores) in measured by spirometry
|
6 months after hospital discharge
|
|
Cerebral microbleeds
Periodo de tiempo: 6 months after hospital discharge
|
Number and anatomical distribution of cerebral microbleeds in MRI imaging of the brain
|
6 months after hospital discharge
|
|
Plasma matrix metalloproteinases -8, -9 and TIMP-1 6 months after hospital discharge
Periodo de tiempo: 6 moths after hospital discharge
|
Plasma matrix metalloproteinases -8, -9 and TIMP-1 levels in ng/mL 6 months after hospital discharge
|
6 moths after hospital discharge
|
|
Plasma neurofilament level and its correlation with global score in neuropsychological test battery
Periodo de tiempo: 6 months after hospital discharge
|
Plasma neurofilament level and its correlation with global score in neuropsychological test battery
|
6 months after hospital discharge
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Correlation ApoE 4 alleles with disease severity
Periodo de tiempo: 6 months post-covid
|
Laboratory analysis of ApoE alleles and comparison of their frequencies among groups
|
6 months post-covid
|
|
Correlation of cerebral microbleeds with neuropsychological global score
Periodo de tiempo: 6 moths after hospital discharge
|
Correlation of type and location of cerebral microbleeds with neuropsychological global score
|
6 moths after hospital discharge
|
|
Association of the incidence of cerebral microbleeds with findings in cardiac MRI
Periodo de tiempo: 6-12 months after hospital discharge
|
Association of the incidence of cerebral microbleeds with findings in cardiac MRI
|
6-12 months after hospital discharge
|
|
Correlation of plasma neurofilament with cerebral microbleeds
Periodo de tiempo: 6 months after hospital discharge
|
Correlation of plasma neurofilament with cerebral microbleeds in brain MR imaging
|
6 months after hospital discharge
|
|
Correlation of 6 minute walk test heart rate variables with cardiac function
Periodo de tiempo: 6-12 months after hospital discharge
|
Correlation of heart rate in rest, exercise and 5 minutes after exercise with cardiac output measured in heart MRI
|
6-12 months after hospital discharge
|
|
Correlation of matrix metalloproteinase 9 with diffusion capacity
Periodo de tiempo: 6 months after hospital discharge
|
Correlation of matrix metalloproteinase 9 (ng/mL) with lung diffusion capacity z-score
|
6 months after hospital discharge
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- HUS/1949/2020
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre COVID-19
-
PfizerActivo, no reclutandoCOVID-19 | Enfermedad por coronavirus 2019 (COVID-19) | Contagio de COVID-19 | Vacunas para COVID-19 | Infección por SARS-CoV-2, COVID19 | Vacunación COVID-19 | Infección por SARS-CoV-2, COVID-19 | COVID-19 (Enfermedad por coronavirus 2019) | Infección por COVID-19 SARS-CoV-2Estados Unidos
-
Shanghai Public Health Clinical CenterAún no reclutando
-
Duke UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Terminado
-
European Institute of OncologyFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; Azienda Ospedaliera Niguarda... y otros colaboradoresTerminado
-
Owlstone LtdCambridge University Hospitals NHS Foundation TrustTerminado
-
Eggensberger OHGBavarian Health and Food Safety Authority (LGL)ReclutamientoCondición posterior a COVID-19 | Publicar COVID-19 | Síndrome post COVID-19 | Síndrome largo de COVID-19 | Condición posterior a COVID-19 (PCC)Alemania
-
Lawson Research Institute of St. Joseph'sCanadian Institutes of Health Research (CIHR); Western University, CanadaReclutamientoFatiga | Síndrome Post-COVID-19 | Condición posterior a COVID-19 | Síndrome Post-COVID | Largo COVID-19 | Largo-COVID | Condición post-COVIDCanadá
-
PfizerReclutamientoEnfermedades de las vías respiratorias | COVID-19 | Neumonía | Enfermedades pulmonares | Enfermedad del coronavirus 2019 | Enfermedad por coronavirus 2019 (COVID-19) | Contagio de COVID-19 | Infecciones del Tracto Respiratorio Superior | Infección del tracto respiratorio | COVID-19 (Enfermedad por coronavirus... y otras condicionesBélgica
-
Yang I. PachankisActivo, no reclutandoInfección respiratoria por COVID-19 | Síndrome de Estrés COVID-19 | Reacción adversa a la vacuna COVID-19 | Tromboembolismo asociado a COVID-19 | Síndrome Post-Cuidados Intensivos COVID-19 | Accidente cerebrovascular asociado con COVID-19Porcelana
-
Population Health Research InstituteMcMaster University; Hamilton Health Sciences CorporationTerminadoCirugía | COVID-19 | Complicación perioperatoriaCanadá